Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome
NCT ID: NCT03122041
Last Updated: 2017-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
30 participants
INTERVENTIONAL
2016-08-31
2016-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight Loss
NCT02941445
Chiglitazar/Metformin in Non-obese Women With PCOS
NCT06125587
Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS
NCT06587698
Simvastatin and Metformin Therapy in PCOS Women. Prospective Randomised Trial.
NCT00396513
Efficacy of Metformin in Lean Women With Polycystic Ovary Syndrome
NCT00319293
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SITA
Sitagliptin (SITA) Lifestyle intervention and sitagliptin 100mg per day for 12 weeks
Sitagliptin
Lifestyle intervention
CON
Controls (CON) Lifestyle intervention
Lifestyle intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sitagliptin
Lifestyle intervention
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* polycystic ovary syndrome (ASRM-ESHRE Rotterdam criteria)
* BMI of 30 kg/m2 or higher
Exclusion Criteria
* significant kidney or hepatic disease
* personal or family history of medullary thyroid carcinoma
* known history of gallbladder disease
* known history of pancreatitis
18 Years
55 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Centre Ljubljana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Simona Ferjan, MD
Principal Investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Metformin Intolerant PCOS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.